BIOAVAILABILITY AND PHARMACOTHERAPEUTICS OF PROMETHAZINE IN HUMAN SUBJECTS
BIOAVAILABILITY AND PHARMACOTHERAPEUTICS OF PROMETHAZINE IN HUMAN SUBJECTS
批准号:
7605387
负责人:
KARL ELMO ANDERSON
金额:
$2.87万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2008-03-31
关键词:
Adverse effectsBed restBiological AvailabilityBloodClinical ResearchCognitiveComputer Retrieval of Information on Scientific Projects DatabaseConditionDataDiagnosisDoseDrowsinessEnvironmentFatigueFundingGrantInstitutionIntramuscularIntramuscular InjectionsInvestigationMeasuresMethodsMicrogravityOralPerformancePharmaceutical PreparationsPharmacodynamicsPromethazineRateRectal SuppositoriesRehabilitation therapyReportingResearchResearch PersonnelResourcesSalivarySourceSpace FlightSpace Motion SicknessTabletsTechniquesTherapeutic IndexUnited States National Institutes of Healthabsorptionbasehuman subjectimprovednovelresponsestable isotope
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Space motion sickness (SMS) is often treated in space with promethazine (PMZ). Common side effects of PMZ administration (50 mg intramuscular) on the ground are drowsiness and impaired cognitive performance. Anecdotal reports indicate that these effects are absent or less pronounced in space. This suggests that the availability of PMZ to the body (bioavailability) and/or the response of the body to PMZ (pharmacodynamics) may change during space flight. Opportunities for clinical research in space are limited. This is a ground-based research needed to improve, or answer specific questions about, diagnosis and therapy during space flight, and post-flight rehabilitation.
We will estimate the bioavailability of an intramuscular injection (IM), oral tablet, and rectal suppository of PMZ in normal subjects during ambulatory and antiorthostatic bed rest (ABR) conditions using novel stable isotope techniques. After three IM doses of PMZ are administered to subjects, we will measure drowsiness, cognitive performance, and salivary flow rate, and will compare them with concentrations of the drug in the blood. We will compare and contrast the bioavailability of PMZ during normal and ABR conditions to examine changes in drug absorption and availability during ABR and evaluate whether these changes may be similar to those anticipated in a microgravity environment. Results of this study will validate methods for an approved in-flight investigation with this medication awaiting an opportunity for manifestation. These data will also provide the much-needed information on the dynamics and therapeutic index of PMZ and their implications on crew fatigue and performance in space.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)
-
批准号:10275566
-
项目类别:
-
资助金额:$49.85万
-
财政年份:2021
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Effect of Oral Cimetidine in the Protoporphyrias (IND 153247 submitted 9/2/2020)
-
批准号:10487494
-
项目类别:
-
资助金额:$40.35万
-
财政年份:2021
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks
-
批准号:8734370
-
项目类别:
-
资助金额:$39.3万
-
财政年份:2013
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks
-
批准号:9338040
-
项目类别:
-
资助金额:$20.76万
-
财政年份:2013
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks
-
批准号:8569008
-
项目类别:
-
资助金额:$33.95万
-
财政年份:2013
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Phase 2 Study of Hemin for Treatment and Prevention of Porphyria Attacks
-
批准号:8921825
-
项目类别:
-
资助金额:$39.76万
-
财政年份:2013
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS
-
批准号:7952131
-
项目类别:
-
资助金额:$1.02万
-
财政年份:2009
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CLINICAL TRIAL: HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA
-
批准号:7952153
-
项目类别:
-
资助金额:$5.95万
-
财政年份:2009
-
负责人:KARL ELMO ANDERSON
-
依托单位:
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)
-
批准号:7952156
-
项目类别:
-
资助金额:$1.78万
-
财政年份:2009
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS
-
批准号:7719167
-
项目类别:
-
资助金额:$1.99万
-
财政年份:2008
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CLINICAL TRIAL: HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA
-
批准号:7719188
-
项目类别:
-
资助金额:$28.45万
-
财政年份:2008
-
负责人:KARL ELMO ANDERSON
-
依托单位:
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)
-
批准号:7719191
-
项目类别:
-
资助金额:$9.96万
-
财政年份:2008
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CYTOCHROME P450 ENZYMES IN HEPATITIS C OXIDATIVE INJURY
-
批准号:7605380
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2007
-
负责人:KARL ELMO ANDERSON
-
依托单位:
GENETIC SUSCEPTIBILITY FACTORS IN PORPHYRIA CUTANEA TARDA (PCT)
-
批准号:7605422
-
项目类别:
-
资助金额:$0.54万
-
财政年份:2007
-
负责人:KARL ELMO ANDERSON
-
依托单位:
HYDROXYCHLOROQUINE VS PHLEBOTOMY FOR PORPHYRIA CUTANEA TARDA
-
批准号:7605417
-
项目类别:
-
资助金额:$7.0万
-
财政年份:2007
-
负责人:KARL ELMO ANDERSON
-
依托单位:
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP
-
批准号:7605391
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2007
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS
-
批准号:7605371
-
项目类别:
-
资助金额:$2.14万
-
财政年份:2007
-
负责人:KARL ELMO ANDERSON
-
依托单位:
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP
-
批准号:7378721
-
项目类别:
-
资助金额:$2.74万
-
财政年份:2006
-
负责人:KARL ELMO ANDERSON
-
依托单位:
CHARACTERIZATION OF ENZYME DEFECTS IN HUMAN PORPHYRIAS
-
批准号:7378696
-
项目类别:
-
资助金额:$0.22万
-
财政年份:2006
-
负责人:KARL ELMO ANDERSON
-
依托单位:
Genetic Susceptibility Factors in Porphyria Cutanea Tarda (PCT)
-
批准号:7905421
-
项目类别:
-
资助金额:$4.78万
-
财政年份:2006
-
负责人:KARL ELMO ANDERSON
-
依托单位:
海外基金